BioSpace News Archive

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccine candidate.

SHINE Technologies, a next-generation fusion technology company, and Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced that they have entered into a clinical supply agreement.

Astellas Venture Management LLC (President: William Watt, Ph.D., “AVM”), and Mission Bay Capital BioLabs (“MBC BioLabs”), today announced their collaboration on the “Astellas Future Innovator Prize” formerly known as the Astellas Golden Ticket competition.

Curis, Inc. announced that the 2nd Annual VISTA Symposium will take place virtually on September 23, 9:00am-1:00pm ET.

Virios Therapeutics, Inc. (Nasdaq: VIRI), announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

WuXi Biologics announced that its two Drug Substance facilities and a Drug Product facility located in Wuxi city received regulatory approvals from the European Medicines Agency and the U.S. Food and Drug Administration.